Journal
CURRENT ONCOLOGY REPORTS
Volume 11, Issue 2, Pages 94-101Publisher
SPRINGER
DOI: 10.1007/s11912-009-0015-5
Keywords
-
Categories
Funding
- Bayer/Onyx
- NATIONAL CANCER INSTITUTE [R01CA121781] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The therapeutic landscape for renal cell carcinoma (RCC) has changed drastically over the past several years with the emergence of molecularly targeted therapies. With previous prognostic and predictive tools based on studies of patients treated with cytokine therapies, confirmation of these prior methods and discovery of new markers in this new era of targeted therapy are of great importance. Alteration of the von Hippel-Lindau gene (VHL) by mutation, loss of heterozygosity, and promoter methylation has been found to be important to RCC pathogenesis. In this review, we discuss the potential role of VHL mutation as a prognostic and predictive marker for RCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available